Thursday, August 27, 2015

Granting of patent for an advanced cardiac biomarker is expected to transform the cardiac biomarker industry

The area of diagnosing and treatment of various cardiovascular diseases have undergone a paradigm change with the introduction of cardiac biomarker. By monitoring the various heart conditions biomarkers can potentially be used to detect and monitor a wide range of cardiac conditions in the critical care setting.
Singulex, Inc., recently announced that the Japanese Patent Office has granted a crucial patent which covers methods for detecting or monitoring cardiovascular conditions by the use of biomarkers Interleukin 17-A (IL-17A)  and cardiac Troponin-I (cTnI) in assays which have high sensitivity. 

Japanese Patent No. 5678045, entitled “Highly Sensitive Biomarker Panels”’ provides patent protection in Japan and it expires by June 2029. The patent is an important development in the industrial landscape of cardiac biomarker recent market dynamics as it impacts the Company's portfolio of 22 issued patents which are connected to its core SMCTM technology and biomarker assays. The company was previously granted United States Patent 8,450,069 covering methods for assessing cardiovascular health and damage by the use of biomarkers cTnI, IL-6, and IL-17A, along with one or more of  BNP & TNF-a, in platform-independent highly sensitive assays. This patent provides the company exclusive commercial rights in US to conduct these these assays through June 2030.
Moreover, as claimed by Japanese patent, one or more of Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-a), along with different forms of B-type natriuretic peptides are used in combination with cTnI and IL-17A as an effective biomarker.

Guido Baechler, President and Chief Executive Officer of Singulex., “We are committed to advancing the clinical understanding and use of high sensitivity biomarkers for the management of chronic diseases, and I am pleased with the continued progress of our clinical programs that support our CLIA-licensed laboratory business as well as our emerging in vitro Diagnostics business, all based upon our Single Molecule Counting technology," 

There are many prominent diagnostic companies which have recently introduced immunoassays for cardiac biomarker testing on an integrated platform, and the leading vendors are pro-active in increasing the efficacy of the systems so that the results are accurate and fast. Prominent market players include Abbott Laboratories, Roche Diagnostics, Alere Inc, Siemens Healthcare, Dickinson and Company and Becton, Bio-Rad Laboratories, and BioMerieux, Randox laboratories. 

Recently, Big Market Research has added a report titled “World Cardiac Biomarkers - Market Opportunities and Forecasts, 2014 -2020”. The report offers a comprehensive insights into the current and future market trends, market profile of leading market players along with detailed segmentation and forecast.

No comments:

Post a Comment